Biomarkers for the clinical evaluation of the cognitively impaired elderly: amyloid is not enough.
about
An expanded role for neuroimaging in the evaluation of memory impairment.Back to the future: Alzheimer's disease heterogeneity revisited.Translation of Pre-Clinical Studies into Successful Clinical Trials for Alzheimer's Disease: What are the Roadblocks and How Can They Be Overcome?Comparison of Automated Brain Volume Measures obtained with NeuroQuant and FreeSurfer.Polygenic hazard score: an enrichment marker for Alzheimer's associated amyloid and tau deposition.
P2860
Biomarkers for the clinical evaluation of the cognitively impaired elderly: amyloid is not enough.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Biomarkers for the clinical ev ...... lderly: amyloid is not enough.
@ast
Biomarkers for the clinical ev ...... lderly: amyloid is not enough.
@en
type
label
Biomarkers for the clinical ev ...... lderly: amyloid is not enough.
@ast
Biomarkers for the clinical ev ...... lderly: amyloid is not enough.
@en
prefLabel
Biomarkers for the clinical ev ...... lderly: amyloid is not enough.
@ast
Biomarkers for the clinical ev ...... lderly: amyloid is not enough.
@en
P2860
P356
P1433
P1476
Biomarkers for the clinical ev ...... lderly: amyloid is not enough.
@en
P2093
James B Brewer
Linda K McEvoy
P2860
P304
P356
10.2217/IIM.12.27
P577
2012-06-01T00:00:00Z